Medicines for Malaria Venture: sustaining antimalarial drug development.
The Medicines for Malaria Venture (MMV) is committed to discovering, developing and delivering new drugs for malaria. Founded in 1999 as a nonprofit organization bringing private sector management methods to bear on a global public health problem, MMV is today recognized as a leader among the public-private partnerships working on diseases for the developing world. Together with its many partners, MMV manages the world's largest malaria research and development portfolio, covering the innovation spectrum from basic drug discovery to late-stage development.
Bathurst
Ian
I
Medicines for Malaria Venture (MMV), International Center Cointrin (ICC) Building, 20 rte de Pré-Bois, 1215 Geneva 15, Switzerland. bathursti@mmv.org
Hentschel
Chris
C
D000962:Antimalarials / Q000145:classification / Q000302:isolation & purification / Q000627:therapeutic use*; D037621:Artemisinins / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015195:Drug Design; D004359:Drug Therapy, Combination; D005582:Foundations; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D012106:Research; D012717:Sesquiterpenes / Q000627:therapeutic use; D035703:Therapies, Investigational
D000962:Antimalarials; D037621:Artemisinins; D012717:Sesquiterpenes; C031327:artemisinin